Class summary at a glance.

Every drug in the Antiprotozoal class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $6.2Mcombined across class
Total Rx claims: 5K4K unique beneficiaries
Generic mfrs (active): 7across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Nitazoxanide

5K Part D claims (CY24) · 4K beneficiaries · First FDA approval: 2020-11-27

3 generic mfrs 36 plans require PA

Low NADAC$87.96

→

Avg plan cost$87.96

Part D spend $6.2M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Pentamidine Isethionate

Brand: NebuPent · 104 Part D claims (CY24) · 40 beneficiaries · First FDA approval: 2001-01-16

4 generic mfrs 329 plans require PA Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $13466

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.